Nanexa AB

Chart & Performance

D1W1MN

P/E

—

P/S

16.66

EPS

—

Div Yield, %

—

Shrs. gr., 5y

48.77%

Rev. gr., 5y

72.50%

Revenues

36m

+48.39%

Net income

-11m

L-54.27%

CFO

-1m

L-94.47%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.

URL

https://nanexa.com/

IPO date

Jun 17, 2015

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title SEK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SEK in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT